United Capital Financial Advisers, LLC Aerie Pharmaceuticals Inc Transaction History

United Capital Financial Advisers, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$28.97 - $48.21 $142,561 - $237,241	-4,921 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$36.32 - $49.25 $178,730 - $242,359	4,921 New	4,921 $234,000
Q4 2018 Feb 14, 2019	SELL	$33.0 - $60.04 $181,500 - $330,220	-5,500 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $717 - $1,056	-15 Reduced 0.27%	5,500 $372,000
Q4 2017 Feb 13, 2018	BUY	$50.85 - $65.1 $101 - $130	2 Added 0.04%	5,515 $330,000
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $631 - $781	13 Added 0.24%	5,513 $268,000
Q2 2017 Aug 14, 2017	BUY	N/A	5,500	5,500 $289,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on United Capital Financial Advisers, LLC with notifications on news.